The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

(2011) K. Sockel et al.   HAEMATOLOGICA

Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

(2011) Jan Krönke et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

(2010) F. Buccisano et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives

(2010) Brunangelo Falini et al.   CURRENT OPINION IN ONCOLOGY

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD

Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity

(2009) Rachel Rau et al.   HEMATOLOGICAL ONCOLOGY

Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient

(2009) Rolf K. Swoboda et al.   INTERNATIONAL JOURNAL OF CANCER

Monitoring minimal residual disease in acute myeloid leukaemia withNPM1mutations by quantitative PCR: clonal evolution is a limiting factor

(2008) Christina Papadaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

(2008) B. Falini et al.   HAEMATOLOGICA

A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin and ARF

(2008) N Bolli et al.   LEUKEMIA

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE